https://www.selleckchem.com/pr....oducts/trastuzumab.h
35-2.73). The secondary safety (clinically relevant non-major bleeding) outcome occurred in 333/15474 patients in the DOAC group (2.2%) and 191/15418 patients in the placebo group (1.2%) with an OR 1.75 (95% CI 1.46-2.1). The extended use of venous thrombolism prophylaxis post-discharge results in decreased venous thromboembolism events but increased bleeding risk. Our cost-effective analysis of extended DOAC use versus placebo showed superiority of the DOAC group. CONCLUSION In conclusion, given the mortality benefit and cost-benef
Synes godt om
Kommentar
Del
